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Abstract
The processes controlling targeting of glucose transporters to apical and baso-
lateral membranes of polarized cells are complex and not-well understood.
We have engineered SGLT1 and GLUT4 constructs linked to fluorescent pro-
teins to highlight the differences in transporter expression and trafficking, in
real time, in different cell types. Activity was assessed in parallel using a FRET
glucose sensor. In COS cells and HEK cells, SGLT1 was distributed between
the plasma membrane and intracellular compartments, but there was little
expression in CHO cells. Trafficking was investigated using the lysosome inhi-
bitors NH4Cl (10 mmol/L) and chloroquine (150 lmol/L) and the protea-
some inhibitors MG-262 (1 lmol/L) and lactacystin (5 lmol/L). Lysosome
inhibitors caused SGLT1 accumulation into intracellular bodies, whereas pro-
teasome inhibitors induced SGLT1 accumulation in the plasma membrane,
even in CHO cells. Our data suggest that a fraction of SGLT1 is rapidly
degraded by lysosomes and never reached the plasma membrane; another frac-
tion reaches the membrane and is subsequently degraded by lysosomes follow-
ing internalization. The latter process is regulated by the ubiquitin/proteasome
pathway, acting at a late stage of the lysosomal pathway. Using the cholesterol
inhibitor MbCD (3 mmol/L), a dominant negative dynamin (K44A) and cave-
olin, we showed that SGLT1 internalization is lipid raft-mediated, but cave-
olin-independent. In contrast, GLUT4 internalization is dynamin-dependent,
but cholesterol-independent. The physiological relevance of these data is dis-
cussed in terms of differential membrane compartmentalization of the trans-
porters and expression under stress conditions.
Introduction
In intestinal absorptive cells and epithelial cells of the kid-
ney, glucose (and galactose) is absorbed from the lumen,
against its gradient, by the electrogenic Na/glucose co-
transporter SGLT located in the brush-border or apical
membrane – among the many isoforms, SGLT1 is most
abundant in the small intestine, whereas SGLT2 is almost
exclusively found in kidney (Wright et al. 2011). The
energy for uphill sugar transport is provided by the
sodium electrochemical potential gradient. The sugar that
accumulates in the cell, due to SGLT-dependent trans-
port, exits down its gradient, across the basolateral mem-
brane and into the blood, via the facilitative glucose
transporter GLUT (Wright et al. 2011). Thus, the location
of SGLT at the apical membrane and of GLUT at the
basolateral membrane is critical for the unidirectional
transport of glucose across epithelia. It remains that little
is known about the processes that target the two trans-
porters to their respective membrane compartments.
The density of proteins in the plasma membrane
involves a balance between insertion and retrieval. One or
both of these processes may be regulated to increase or
decrease the level of protein in the plasma membrane. In
most cells, insertion involves exocytotic vesicles that bud
from the trans Golgi network (TGN), or vesicles that
recycle from the early endosome. In polarized epithelial
cells, protein insertion is more complex since some pro-
teins are targeted to the basolateral membrane, while
others end up in the apical membrane. The targeting to
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the basolateral membrane is relatively straightforward and
involves exocytotic vesicles originating from the TGN. In
contrast, targeting to the apical membrane may involve a
direct route from the TGN to the apical membrane or a
transcytosis pathway where proteins transit by the baso-
lateral membrane before reaching the apical membrane
(Rodriguez-Boulan et al. 2005; Lakkaraju and Rodriguez-
Boulan 2007; Sato et al. 2007).
Retrieval of proteins from the plasma membrane
remains the subject of many studies. Three broad cate-
gories have been identified for internalization of mem-
brane-bound proteins, extracellular particles, or
membrane components in general. These categories
involve lipid raft, clathrin-coated pits, or phagocytosis.
Lipid raft-mediated endocytosis may be further divided
into caveolin-dependent and independent pathways
(Le Roy and Wrana 2005; Ivanov 2008; El-Sayed and
Harashima 2013; Parton and del Pozo 2013). Methyl-
b-cyclodextrin (MbCD), which depletes cholesterol from
membrane’s rich domains, is widely used to study mem-
brane proteins that are internalized via caveolin-depen-
dent or -independent pathways. In this case, inhibition of
lipid raft-dependent endocytosis by MbCD increases
insertion of the selected proteins in the plasma membrane
(Roepstorff et al. 2002; Ivanov 2008). Accordingly, based
on the observation that MbCD decreases both the activity
and insertion of SGLT1 into the apical membrane, it has
been suggested that cellular cholesterol stabilizes SGLT1
into the apical membrane (Suzuki et al. 2006). The
GTPase dynamin regulates both the clathrin and caveolin-
dependent pathways, but more importantly, does not reg-
ulate the lipid raft endocytotic pathway, which is cave-
olin-independent (Achiriloaie et al. 1999; Yao et al. 2005;
El-Sayed and Harashima 2013). A dominant negative
dynamin (K44A) has been identified that prevents inter-
nalization of membrane-bound proteins that use caveolin-
and clathrin-dependent pathways for retrieval (Oh et al.
1998; El-Sayed and Harashima 2013). We have used both
MbCD and dynamin K44A to characterize SGLT1 and
GLUT4 internalization and found that SGLT1 internaliza-
tion is lipid raft mediated, but caveolin-independent,
while GLUT4 endocytosis is dynamin-dependent and,
more importantly, MbCD-independent.
Membrane-bound proteins are degraded by the endo-
some/lysosome pathway, while cytosolic proteins, or mis-
folded proteins from the ER are degraded by the
ubiquitin/proteasome pathway. However, ubiquitin also
tags membrane-bound receptors and channels such as
EFGR, GHR, and connexin43 (Cx43) to facilitate their
internalization and degradation by lysosomes. In this
instance, proteasome inhibitors may block a late stage of
the lysosomal pathway and, as a result, increase protein
recycling between the early endosome and the plasma
membrane (Laing et al. 1997; van Kerkhof et al. 2001;
Longva et al. 2002; Alwan et al. 2003). Our experiments
carried out with three different cell lines, and several lyso-
some and proteasome inhibitors indicate that SGLT1
expression and targeting is similar to that of Cx43. Also,
as with EGFR and GHR (van Kerkhof et al. 2001; Longva
et al. 2002; Alwan et al. 2003), lysosome inhibitors target
SGLT1 to intracellular bodies and proteasome inhibitors
increase membrane insertion of SGLT1, by inhibiting very
likely the lysosomal pathway.
Experimental Procedures
Solutions and experimental techniques
The bath solution for cell imaging consisted of (in mmol/
L) 140 NaCl, 5 KCl, 1.1 MgCl2, 2.5 CaCl2, 10 HEPES,
with the pH adjusted to 7.2 with KOH. Glucose was
added to this solution and for the 0 glucose solution, N-
methyl-D-glucamine (NMDG) was added to maintain the
solution’s osmolarity. Solutions were perfused directly
over the cells using a gravity fed eight ways perfusion
device (Warner Instruments, Hamden, CT) with electri-
cally controlled solenoids (The Lee Company, Westbrook,
CT). Input and output of solution volumes to the record-
ing chamber (35 mm glass bottomed culture dish) were
equilibrated to maintain constant flow rates and pressures
within the recording chamber. Incubation of the cells
with the various chemicals was carried out at 37°C and
the imaging was done at room temperature (25°C). The
cholesterol inhibitor (MbCD), chloroquine and other
chemicals were purchased from Sigma-Aldrich Corp. (St.
Louis, MO). The proteasome inhibitor III and lactacystin
were purchased from Calbiochem.
Plasmids constructs and transfection
We obtained the FLIPglu-700 lmol/L cDNA from Dr.
W.B. Frommer, GLUT4 from Dr. D. Abel, and human
SGLT1 from Dr. E. Wright. The following plasmids were
obtained from Addgene:Lamp1-YFP (Addgene plasmid
1816), GFP EEA1 (Addgene plasmid 42307), Lyn-tailed
mCherry-SEpHluorin, (Addgene plasmid 32002) – The
latter had the SEphlorin removed to make the plasma
membrane marker PM-mCherry, using the N-terminal
motif of the Src family kinase Lyn (Koivusalo et al.
2010), Dynamin wt (Addgene plasmid 34684), and Dyn-
mamin dominant negative (Addgene plasmid 34685).
Caveolin was obtained from Origene. Caveolin was fused
at the C-terminus to mCherry/CFP. Human SGLT1 with
insertions of YFP or CFP was generated by inserting a
HindIII site at the individual amino acids of 55, 595 and
subcloning into the restriction site a HindIII flanked YFP
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or CFP. All constructs were subcloned into the mam-
malian expression vectors with the CMV promoter. The
IgKappa signal sequence (Invitrogen, Carlsbad, CA) was
added to the N-terminus of the fusion protein YFP/
CFPSGLT1 to induce insertion of the functional construct
into the plasma membrane. Transient transfections of all
cell lines with all constructs were done after 1 to 2 days
in culture with Lipofectamine 2000 (Invitrogen). Expres-
sion of the constructs was sufficiently high after 36–48 h
to perform radioactive uptake, protein isolation for west-
ern blots, and microscopy imaging.
FRET imaging
All cells were imaged live without fixation. Images (16-bit)
were acquired using a Nikon Eclipse TE300 microscope fit-
ted with a 60X (N.A. 1.4) oil immersion lens (Nikon
Instruments Inc., Melville, NY) and equipped with a filter
cube comprising a CFP bandpass excitation filter: 436/20b,
together with a longpass dichroic mirror: 455DCLP
(Chroma Technology Corp, Rockingham, VT). LED’s
(Lumileds; San Jose, CA) were used as light sources: one
emitting at 455  20 nm (royal blue) and the other emit-
ting at 505  15 nm (cyan). LED’s and camera exposure
were controlled by MetaFluor Imaging 6.1 software (Molec-
ular Devices Corp., Sunnyvale, CA). Ratiometric FRET
measurements were monitored from the Yellow Fluorescent
Protein (YFP) and Cyan Fluorescent Protein (CFP) images
acquired simultaneously using a Dual View image splitter
(Optical Insights, Tucson, AZ) equipped with a 505 nm
long-pass dichroic filter to separate the CFP and YFP sig-
nals, a CFP emission filter (480/30) and a YFP emission fil-
ter (535/40) (John et al. 2008, 2011). Images were captured
with a Cascade 512B digital camera (Photometrics, Tucson,
AZ). Exposure times were optimized in each case but var-
ied between 300 and 500 ms and were recorded at a con-
stant rate for each cell between 0.2 and 0.33 Hz. Many
experiments lasted more than 1 h leading to a slow drift in
the FRET ratio baseline in some cases.
Standard microscopy imaging
Standard microscopy images were acquired using an
Olympus IX70 inverted microscope (Olympus America
Inc., Center Valley, PA) fitted with an Olympus plan apo
609, 1.4 N.A. oil immersion objective and a cooled CCD
camera (Model Quantix, Photometrics, Tucson, AZ).
Imaging Workbench software was used for data acquisi-
tion and analysis. YFP (XF104-2) and CFP (XF130-2) filter
cubes were purchased from Omega Optical Inc. Confocal
images were acquired using on a Zeiss Axiovert 100 LSM
inverted microscope fitted with a 609 water immersion
objective (Zeiss CApochromat 63/1.2 W Corr). Zeiss
Pascal 5 image software (Carl Zeiss, Inc., Thornwood, NY)
was used for data acquisition and analysis.
Immunoblot analysis
For immunoblot analyses, cells were lysed in a buffer con-
taining 50 mmol/L Tris, pH 7.5, 1% Triton X-100,
150 mmol/L NaCl, 10% glycerol, and 1 mmol/L EDTA.
Samples were size fractionated by SDS-Page (10%) and trans-
ferred to nitrocellulose membrane (Biorad, Hercules, CA).
Immunodetection was performed using the following
primary antibodies, goat anti-Actin (I-19) (diluted 1:500),
rabbit anti-GFP (FL) (diluted 1:200) all purchased from
Santa Cruz Biotechnology, Inc., Santa Cruz, CA. As sec-
ondary antibodies, we used rabbit anti-goat Ig/peroxidase,
goat anti-rabbit Ig/peroxidase, and goat anti-mouse Ig/
peroxidase (all diluted 1:5000), all purchased from Sigma-
Aldrich. For quantitative analysis, revelation was per-
formed using the Luminata Forte Western HRP Substrate
as describe by the manufacturer Millipore (Temecula,
CA). Chemiluminescence images were acquired using an
Image Reader LAS-3000 LCD camera (Fujifilm, Stamford,
CT). Band intensities were quantified using National
Institutes of Health ImageJ software.
Quantitative analysis of SGLT1 localization
Differential Localization of SGLT1-YFP in the cytoplasm
and plasma membrane was quantified using the intensity
profile method developed by ImageJ. The nuclear region
was excluded when drawing the profiles. We also attempted
to pick regions, from the membrane and cytoplasm, that
exhibited uniform fluorescence intensity i.e., “hot spots”
were excluded. To quantify the degree of membrane inser-
tion, we first estimated the areas under the peaks of fluo-
rescence, which correspond to membrane-bound SGLT1.
These values were then normalized to the cell area laying
below the profile. Ten measurements were carried out in
all cases.
Statistical analysis
For each data set, the mean and accompanying 95% con-
fidence intervals (CIs) are reported. The conventional per-
centile bootstrap-resampling approach with 10,000
replications was used for estimating 95% CI as well as
examining the significant difference between groups (ef-
fect size statistics) (Efron and Tibshirani 1991; Nakagawa
and Cuthill 2007; Calmettes et al. 2012). A P-value <0.05
was considered statistically significant. All analyses were
performed by subroutines for bootstrapping developed in
the Python programming language (van Rossum and
Drake 2001), using the Numpy (Oliphant 2001) and Scipy
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(Jones et al. 2001) packages, based on the code we previ-
ously published (Calmettes et al. 2012).
Results
Generating SGLT1 constructs linked to YFP
or CFP
The regulation of GLUT insertion in the plasma mem-
brane has been extensively studied and is reasonably well-
understood (Hou and Pessin 2007). In comparison, less is
known about the regulation of SGLT insertion in the
plasma membrane. We have generated several SGLT1 con-
structs linking the fluorophores YFP or CFP at different
locations to study this process. In generating constructs,
we were looking for functional and nonfunctional trans-
porters that translocated to the membrane. The rationale
behind this approach was to assess whether activity modu-
lates transporters’ membrane insertion or retrieval. To
measure function – that is glucose transport – we employ
a well-established technique, based on cell’s transfection
with a FRET glucose biosensor, which allows recording of
glucose fluxes and metabolism in single cells (John et al.
2011; Calmettes et al. 2013). Out of the many constructs
that we generated, we focused on one active and one inac-
tive construct, which had both very good level of expres-
sion and were translocating to the plasma membrane.
Many of the constructs that we generated were nonfunc-
tional and the one we picked for our study had the fluo-
rophore inserted at residue 595 (SGLT1-595YFP).
Generating a functional transporter with CFP or YFP was
challenging, and we found that linking the fluorophore to
the N terminus, which can be altered and still allow for
normal protein folding (Faham et al. 2008), yielded func-
tional transporter activity. To further facilitate protein
insertion into the plasma membrane, we inserted a Signal
Sequence in front of the fluorophore at the N terminus
(see Materials and Methods). This construct denoted SS-
CFP-SGLT1, had a five residues linker between CFP and
SGLT1, and transported glucose as the wt SGLT1 (Fig. 1).
To validate our functional assay, we also generated a simi-
lar construct with SGLT2 (SS-CFP-SGLT2) that we over-
expressed in COS cells. Data in Fig. S1 show that the
SGLT2 construct generated very little glucose uptake com-
pared to SGLT1 under the same conditions. The very low
transport activity of SGLT2 compared to SGLT1 is consis-
tent with previous reports (Hummel et al. 2011).
Translocation of SGLT1 and GLUT4 to the
plasma membrane of HEK, COS, and CHO cells
Trafficking of SGLTs to the plasma membrane in polarized
cells is poorly understood. To study this process, we
transfected SGLT1 linked to YFP or CFP into HEK, COS,
and CHO cells. Experiments were carried out with both
SGLT1-595YFP and SS-CFP-SGLT1. Trafficking of these
two constructs was qualitatively the same and we will use
the denotation SGLT1-YFP/CFP in the rest of the text to
designate the two constructs. In considering SGLT1 traf-
ficking, we assumed that trafficking of SGLT1 in these cell
lines follows a classical pathway, wherein after synthesis,
the protein moves to the trans Golgi network (TGN) and
from there to the plasma membrane via exocytotic vesicles
(Fig. 2). Insertion is then balanced by retrieval mecha-
nisms, which target the protein to the lysosomal pathway
or back to the plasma membrane via a recycling process,
involving the early endosome. Figure 2 shows that SGLT1-
YFP is observed at all of these steps – that is, TGN, exocy-
totic vesicles, plasma membrane, and endosome, support-
ing the hypothesis that trafficking of SGLT1 uses a
conventional pathway. In this study, we focused our atten-
tion on the endocytosis and degradation processes. There
are two main of endocytotic pathways, which are either
mediated via clathrin coated pit or lipid raft; the lipid raft-
mediated pathway may be further divided into caveolin-
dependent or -independent pathways. Both the clathrin-
and caveolin-dependent pathways are modulated by the
Figure 1. SGLT1-dependent glucose transport in COS cells. The
differences in FRET ratios in Fig 1 illustrate how overexpression of
wt SGLT1 and fluorescent construct SS-CFP-SGLT1 modulate
glucose entry in COS cells expressing the FRET- based glucose
sensor Flip 600 lmol/L. In this panel, three traces are superimposed
that were obtained in three sets of experiments with COS cells
expressing either wt SGLT1, SS-CFP-SGLT1 or no SGLT1. At the
beginning of the traces, glucose entry resulting from the addition
of 10 mmol/L glucose to the bath was mediated by both
endogenous GLUTs and overexpressed SGLT1. In all three cases,
glucose efflux following bath glucose removal was mediated via
endogenous GLUTs. In the middle of the traces, 10 lmol/L CytoB
was added to the bath to block endogenous GLUTs. Under these
conditions, addition of 10 mmol/L glucose to the bath evoked
glucose entries of similar amplitude with cells expressing wt SGLT1
and SS-CFP-SGLT1, indicating that SS-CFP-SGLT1 is fully functional.
The fact that there is no glucose entry in cells that do not
overexpress SGLT1, suggest that there is no detectable endogenous
SGLT activity in COS cells.
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GTPase dynamin that constricts and pinches the endocy-
totic vesicles from the membrane (Henley et al. 1998; El-
Sayed and Harashima 2013; Parton and del Pozo 2013). To
characterize SGLT1-YFP/CFP internalization, we used two
approaches. First, we used the dynamin-dominant negative
K44A, which prevents pinching off of endocytotic vesicles
and causes accumulation of the membrane vesicle’s con-
tent in the plasma membrane (Oh et al. 1998; El-Sayed
and Harashima 2013). Second, we used the cholesterol
inhibitor MbCD, which prevents endocytosis of choles-
terol-dependent vesicles.
Under normal culture conditions (DMEM), both the
YFP and CFP constructs exhibited similar cellular distribu-
tions. In HEK cells, a large fraction of SGLT1-YFP/CFP was
in the cytoplasm – likely associated with endosomes – while
a small fraction was inserted into the plasma membrane
(Fig. 3A). In COS cells, a larger fraction of the SGLT1-YFP/
CFP was located in or at the plasma membrane (Fig. 3B).
In CHO cells, there was little or no expression of the con-
structs (Fig. 3C). We hypothesized in this case that SGLT1-
YFP/CFP’s degradation was more rapid than its synthesis.
Data are presented later that support this hypothesis.
We next tested the effects of the cholesterol inhibitor
MbCD on SGLT1-YFP/CFP internalization in HEK and
COS cells. Incubation of HEK and COS cells expressing
SGLT1 with 3 mmol/L MbCD for 6–12 h caused a signifi-
cant increase of SGLT1 insertion into the plasma mem-
brane (Fig. 3D and E) (See confocal images in Fig. S2
showing co-localization of SGLT1 with the plasma mem-
brane marker PMmCherry), suggesting that SGLT1 inter-
nalization is lipid raft-mediated. On the other hand,
MbCD had no effect on GLUT4-YFP distribution in either
cell type. The transporter remained associated with intra-
cellular compartments, even after a 12-h incubation in the
presence of the inhibitor (result not shown), suggesting
that GLUT4 internalization is not lipid raft-mediated.
When clathrin- or caveolin-mediated endocytosis was
inhibited with overexpression of the dominant negative
dynamin K44A, SGLT1-YFP/CFP insertion in the plasma
membrane did not increase (Fig. 4A, B and E), indicating
that SGLT1 internalization is not clathrin- or caveolin-
dependent. In contrast, under the same conditions, inser-
tion of GLUT4-YFP into the plasma membrane increased
dramatically (Fig. 4C, D and E). This result is consistent
with GLUT4 internalization being primarily clathrin-
dependent (Al-Hasani et al. 1998; Kao et al. 1998; Hou
and Pessin 2007; Hou et al. 2009). On this basis, we con-
clude that internalization of GLUT4 and SGLT1 follow
different pathways.
Our dynamin and MbCD data indicate that internaliza-
tion of SGLT1 is lipid raft-mediated, but not caveolin-
dependent. However, there are reports that overexpression
of caveolin 1 (Cav1) increases the transporter’s activity by
stabilizing SGLT in the plasma membrane (Runembert
et al. 2002; Lee et al. 2012; Elvira et al. 2013). To test
whether Cav1 had a similar stabilizing effect in our cell
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Figure 2. SGLT1 trafficking uses a classical pathway in HEK and COS cells. Depending on the experimental conditions, our data show that
SGLT1-YFP may be found in the trans Golgi network (TGN) (1), vesicles (2), the plasma membrane (3), or endosome (4). These images suggest
that insertion and retrieval of SGLT1 in and out of the membrane follows a classical pathway. This diagram also specifies the modulator of
endocytosis and degradation that were used and their potential sites of action. The letter “A” identifies the trafficking of proteins from the
TGN to lysosome and “B” identifies the trafficking of endocytosed proteins from the plasma membrane to lysosome. The mode of action of
the GTPase dynamin is also identified in this diagram.
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Figure 3. The cholesterol inhibitor MbCD enhances insertion of SGLT1 in the plasma membrane. In HEK cells (A) and COS cells (B), and under
normal culture conditions (DMEM), SGLT1-YFP is primarily located inside the cells in small vesicles and in larger structures identified as
endosomes. In contrast, there is almost no SGLT1 expression in CHO cells. An image of a transfected CHO cells is shown in (C) for reference,
but only 10–12 transfected cells were found in an entire 1.5 cm dish per experiment. Incubation overnight with the cholesterol inhibitor MbCD
(3 mmol/L) facilitates insertion of SGLT1 in the membrane in HEK cells (D) and COS cells (E). In CHO cells, incubation with MbCD had no effect
(F) and the number of transfected cells remained very low. In (G), the left panels show fluorescence intensity profiles for each condition. The
graph in the right panel shows a quantification of SGLT1-YFP insertion in the plasma membrane, using five different intensity profiles for each
condition (see Experimental Procedures for details).
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+ Dynamin K44A
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Figure 4. In HEK cells, the dynamin dominant negative K44A facilitates GLUT4 insertion in the plasma membrane, but has no effect on SGLT1
trafficking. Panels A (SGLT1-YFP expressed in the absence of K44A) and B (co-expression of SGLT1 with K44A) shows that SGLT1 remains
associated with intracellular compartments when co-expressed with K44A (B). In contrast, GLUT4-YFP, which is also mostly localized to
intracellular compartments under normal conditions (C) is directed to the plasma membrane when co-expressed with K44A (D). Panel E shows
the fluorescence intensity profiles for each condition. The graph in the right panel shows quantifications of SGLT1-YFP and GLUT4-GFP
insertion in the plasma membrane.
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systems, we carried out a number of experiments to assess
whether (i) the level of Cav1 in the membrane correlates
with that of SGLT1-YFP and Cav1-mCherry and (Ima-
mura et al. 2009) SGLT1-YFP co-localize in the mem-
brane. First, in agreement with others, we found that
overexpression of Cav1 increased SGLT1-YFP insertion
into the plasma membrane by 2.5 fold (Fig. 5A, B, and
E). However, the increased SGLT1’s insertion in the
plasma membrane was not associated with accumulation
of Cav1 in the plasma membrane. Indeed, the dominant
negative dynamin K44A, which prevents Cav1
internalization and increase Cav1 level in the plasma
membrane (Achiriloaie et al. 1999; Yao et al. 2005; El-
Sayed and Harashima 2013), had no effect on SGLT1-
YFP insertion in the plasma membrane (Fig. 4B). As a
control to test whether dynamin regulates Cav1 internal-
ization in our cell systems, we co-expressed the dynamin
K44A mutant with Cav1-CFP. Data in Figure 5C and D
show that dynamin K44A causes aggregation of Cav1-CFP
in membrane “hot spots”. In addition, incubation of
HEK cells with the proteasome inhibitor, MG-262, which
facilitates insertion of SGLT1 in the plasma membrane,
Control
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Figure 5. Caveolin 1 (Cav1) does not regulate SGLT1 trafficking in HEK and COS cells. Lipid raft-dependent endocytosis may be caveolin-
dependent or independent. Overexpression of Cav1 with SGLT1-YFP in HEK cells causes accumulation of SGLT1 in the plasma membrane (B
and E). However, as shown in (F), there is no co-localization between SGLT1-YFP and Cav1-CFP. When expressed alone, Cav1-CFP is targeted
to “hot spots” in the plasma membrane, but is also localized to intracellular compartments (C). When co-expressed with the dynamin-
dominant negative K44A, there is a strong accumulation of Cav1-CFP in the plasma membrane (D). These data contrast with that in Panels A
and B of Fig 4 where K44A had no effect on SGLT1 trafficking. Panel E shows the fluorescence intensity profiles for (A) and (B). The graph in
the right panel shows quantifications of SGLT1-YFP insertion in the plasma membrane for (A) and (B).
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had no effect on Cav1-CFP accumulation in the mem-
brane. Finally, co-expression of Cav1-mCherry together
with SGLT1-YFP failed to demonstrate any significant co-
localization of the two proteins (See confocal images in
Fig. S3 showing the lack of co-localization between
SGLT1-YFP and Cav1-mCherry). These results strongly
suggest that there is no correlation between the levels of
Cav1 and SGLT1 in the plasma membrane. Thus, SGLT1
stabilization by Cav1 may be indirect and involve inter-
mediary regulatory proteins, such as PI3K or PKC as
reported elsewhere (Oka et al. 1997; Zundel et al. 2000).
Regulation of SGLT1 translocation by
metabolic inhibitors
Membrane endocytosis is regulated by ATP and phos-
phatidylinositol-bis 4,5-phosphate (PIP2) synthesis. This
ATP/PIP2-dependent process is clathrin-, dynamin-, and
calcineurin-independent, but is blocked by MbCD (Lariccia
et al. 2011). Accordingly, in polarized epithelial cells, the
phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin,
increases protein levels in the plasma membrane by pre-
venting their degradation (Hansen et al. 1995; Kjeken et al.
2001). To test whether retrieval of SGLT1 from the plasma
membrane is ATP-dependent, we lowered intracellular
ATP with 100 lmol/L iodoacetate (IAA), a glycolytic inhi-
bitor, or 1.5 mmol/L NaCN, a blocker of oxidative phos-
phorylation. Data in Figure 6 show that IAA promoted
accumulation of SGLT1 in the plasma membrane within
6 h (B), but NaCN had no effect even after 12 h (C). Simi-
larly, FCCP, which uncouples mitochondria, had no effect
either on SGLT1 trafficking (data not shown). This differ-
ential effect of IAA and NaCN or FCCP on SGLT1 translo-
cation probably reflects the greater dependence of these
cells on glycolytic rather than oxidative ATP production.
To investigate whether this effect of ATP was mediated via
PIP2 synthesis, we incubated HEK with 1 lmol/L wort-
mannin. After 6–9 h, there was a significant increase in
SGLT1YFP/CFP insertion in the plasma membrane
(Fig. 6G), supporting the hypothesis that endocytosis and
recycling of SGLT1 is both ATP- and PIP2-dependent.
Degradation of SGLT1 by proteasome and
lysosome
Although CHO cells are routinely used as an expression
system for many proteins, including GLUTs, ion channels,
hexokinases, and FRET-based sensors (John et al. 2011),
the level of expression of our SGLT1 constructs in these
cells was very low. Consistent with this low level of expres-
sion, we found that the activity of SGLT1 wt in CHO cells
was low compared to that with HEK cells. Low expression
of SGLT1 may reflect a lack of protein synthesis or a high
rate of protein degradation. Protein degradation may fol-
low one of two pathways: the lysosomal pathway used
preferentially by membrane-bound proteins, or the protea-
somal pathway used by cytosolic proteins. To investigate
SGLT1 degradation, we first incubated CHO cells express-
ing SGLT1-YFP/CFP with the lysosomal pathway inhibi-
tors chloroquine (150 lmol/L) and NH4Cl (10 mmol/L).
Within 2 to 4 h following addition of the inhibitors,
SGLT1-YFP/CFP begun to accumulate in lysosomes
(Fig. 7B) (See confocal images in Fig. S4 showing SGLT1-
YFP/CFP co-localization with Lamp1-mCherry), suggest-
ing that SGLT1-YFP/CFP is rapidly degraded via the lyso-
somal pathway. We then incubated the cells with the
proteasome inhibitors MG-262 (1 lmol/L) and lactacystin
(5 lmol/L). Again, within 2 to 4 h, SGLT1YFP/CFP
expression increased. In this case, however, the fluores-
cence was associated with the plasma membrane and an
intracellular compartment different from lysosomes
(Fig. 7C). Even though SGLT1-YFP/CFP expression could
be observed after 2 to 4 h with both either types of inhibi-
tor, the expression level did not reach maximum until 6–
9 h. Furthermore, the inhibitors did not have to be pre-
sent during that time for the expression to reach maxi-
mum, in fact a short initial 2-h incubation was sufficient.
Based on these results, we conclude that synthesis and
degradation of SGLT1 in CHO cells are fast processes, tak-
ing place within hours. Both the lysosomal and proteoso-
mal pathways prevent SGLT1 degradation, even though
their effects are dramatically different. To confirm the dif-
ferential effects of the lysosome and proteasome inhibitors,
the same experiments were carried out in HEK and COS
cells (Fig. 7D–I). Similar qualitative results were obtained
with these cells. In both cases, the lysosome inhibitors
chloroquine (150 lmol/L) and NH4Cl (10 mmol/L)
induced SGLT1 accumulation in lysosomes after several
hours, with the density of the lysosomes increasing during
the following 4–6 h. Moreover, as with CHO cells, there
was no accumulation of SGLT1-YFP in the membrane
after treatment with lysosome inhibitors (7E and H),
whereas accumulation occurred following incubation with
proteasome inhibitors. It should be noted that the protea-
some inhibitors had slightly different effect in CHO cells
and HEK cells. In the latter, the inhibitors did not cause
accumulation of SGLT1-YFP in intracellular bodies, and
most of SGLT1-YFP/CFP was inserted into the plasma
membrane (Fig. 7F).
The respective role of the lysosomal and
proteosomal pathways in SGLT1
degradation
The lysosomal inhibitor data show that SGLT1-YFP/CFP
is mainly targeted to lysosomes for degradation, whereas
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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SGLT1-YFP/CFP is targeted to the plasma membrane in
the presence of proteasome inhibitors. These results raise
two questions: (i) Is newly synthesized SGLT1 directly
targeted to lysosome for degradation, or is SGLT1 first
targeted to the plasma membrane before being degraded
by lysosomes; and (ii) is SGLT1 directly degraded by the
proteasome, or is the effect of proteasome inhibitors
indirect and mediated via inhibition of the lysosomal
degradation pathway? To answer the first question, we
incubated HEK cells expressing SGLT1-YFP/CFP with the
cholesterol inhibitor, MbCD, for 12–24 h to target SGLT1
to the plasma membrane (Fig. 8A), and then added the
lysosome inhibitor chloroquine for an additional 3–4 h
(Fig. 8B). Few hours after adding the lysosomal inhibitor
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Figure 6. Effects of metabolic inhibitors on SGLT1 trafficking. Vesicle exocytosis and endocytosis are processes that require energy. We tested
the effects of inhibitors of ATP production by glycolysis (IAA) and TCA cycle (NaCN) on SGLT1 trafficking. Incubation with 150 lmol/L IAA
caused SGLT1 insertion in the plasma membrane within 1–2 h in HEK cells (B) and COS cells (E). In contrast, incubation with NaCN (1.5 mmol/
L) had no effect on SGLT1 trafficking in either HEK (C) and COS cells (F). The inhibitor of PI3 kinase, wortmannin causes accumulation of
SGLT1 in the plasma membrane (G), suggesting that the effect of ATP is due in part to activation of PI3 kinase. Panel H shows the fluorescence
intensity profiles for each of the condition illustrated in Panels (A) to (G). The lower graph shows quantifications of SGLT1-YFP insertion in the
plasma membrane for each condition from (A) to (G).
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in the presence of MbCD, there was strong labeling of
the lysosomal compartment by SGLT1-YFP/CFP, but no
additional insertion into the membrane (Fig. 8B), sug-
gesting that a large fraction of the newly synthesized
SGLT1-YFP is directly targeted to lysosomes for degrada-
tion. This is consistent with data obtained with other
membrane-bound proteins where a large fraction of newly
formed proteins is directly targeted to lysosomes for
degradation, and only a small fraction is targeted to the
plasma membrane where it is stabilized and active. The
latter fraction is then subsequently recycled to the plasma
membrane or to lysosomes for degradation following
endocytosis.
We next did the same experiment using a proteasome
inhibitor instead of a cholesterol inhibitor. In this case,
HEK cells expressing SGLT1-YFP/CFP were first incu-
bated with the proteasome inhibitor MG262 for 4–6 h
(Fig. 8C), and then exposed to the lysosome inhibitor for
another 3–4 h (Fig. 8D). In this case, there was no signif-
icant targeting of SGLT1-YFP/CFP to the lysosomal com-
partment after addition of lysosome inhibitors. In fact,
the level of transporter kept increasing in the plasma
membrane for the next 6–8 h (Fig. 8D). Consistent with
previous reports (van Kerkhof et al. 2001), these results
suggest that the proteasome inhibitors block the lysoso-
mal pathway at a late stage. To further test the hypothesis
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Figure 7. Proteosomal- and lysosomal-dependent degradation of SGLT-YFP in CHO, HEK, and COS cells. For the series of experiments depicted
in this figure, we have used the lysosome inhibitors chloroquine (150 lmol/L) and NH4Cl (10 mmol/L) and the proteasome inhibitors MG262
(1 lmol/L) and lactacystine (5 lmol/L). Panel A illustrates, as previously shown in Fig 3C, that there is almost no expression of SGLT1 in CHO
cells under normal culture conditions (A). Addition of the lysosomal inhibitor chloroquine for 4–8 h causes SGLT1-YFP accumulation in what
appears to be the membrane of large vesicles identified as lysosomes (B). Incubation with NH4Cl for the same period of time had a similar, but
perhaps lesser effect (not shown). Incubation with the proteasome inhibitor MG262 also causes expression of SGLT1-YFP in CHO cells, but in
this case, a large fraction of the protein was targeted to the plasma membrane (C). Bar graph data in panel (J) indicate that SGLT1 increased
insertion of SGLT1 in the plasma membrane in response to MG262 was not associated with increased glucose uptake. The same experiments
carried out in HEK and COS cells showed similar results. Incubation with the lysosome inhibitor, chloroquine, directs SGLT1-YFP to large
lysosomal vesicles within 4 h in HEK cells (E) and COS cells (H). Incubation with the proteasome inhibitor MG262 enhanced SGLT1-YFP insertion
in the plasma membrane after 4–6 h in HEK cells (F) and COS cells (I). However, in the cases of HEK and COS cells, most of SGLT1-YFP was
targeted to the plasma membrane (and the Golgi) and there was little fluorescence associated with intracellular compartments. Incubation with
the proteasome inhibitor lactacystin had the same effects.
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Figure 8. Does SGLT1 traffic via the plasma membrane prior to degradation by lysosomes? To test whether SGLT1 traffics through the plasma
membrane prior to be degraded by lysosomes, we first incubated overnight HEK cells expressing SGLT1-YFP with the cholesterol inhibitor
(MbCD) (A) and added after that the lysosome inhibitor chloroquine to the incubation medium (B). After incubation with MbCD, a large
fraction of SGLT1-YFP is targeted to the plasma membrane (A), but after addition of the lysosome inhibitor, the newly synthesized SGLT1 is
directed to lysosome, with no additional insertion in the plasma membrane (B). These data suggest that a large fraction of the newly
synthesized SGLT1 is targeted to lysosomes. We did the same experiments using the proteasome inhibitor. In this case, HEK cells expressing
SGLT1 were first incubated with MG262 for 4–6 h to target the transporter to the plasma membrane (C), then the lysosome inhibitor
choloroquine was added (D). Data in (D) show that, following addition of the inhibitor, SGLT1-YFP was not targeted to lysosomes, but instead
SGLT1-YFP insertion in the plasma membrane was sustained, while labeling of the Golgi increased. Western blot in (E) shows an increase of
34.5% (n = 2) of SGLT1-YFP protein level after 8 h incubation in the presence of the proteasome inhibitor MG262 (1 lmol/L). Actin (lower
band) was used to normalize the protein levels obtained with and without incubation with MG262.
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that increased membrane insertion results from blocking
of the degradation pathway rather than simple recycling
of cytosolic proteins, we carried out western blot analysis
to estimate the level of SGLT1-YFP, before and after a
8 h incubation, in the presence of 1 lmol/L MG262. As
shown in Figure 8E, the SGLT1-YFP level increased by
34.5% (n = 2) in the presence of the inhibitor, support-
ing the hypothesis that this effect is indeed mediated by
blocking of the degradation pathway.
Discussion
We generated SGLT1 fluorescent constructs to study the
trafficking of SGLT1-YFP/CFP in real time in three differ-
ent cell types. Activity of SGLT1-YFP/CFP and SGLT1
WT was assessed in parallel experiments, with a FRET-
based glucose sensor. Using live imaging techniques, we
observed that translocation of SGLT1-YFP/CFP is highly
regulated and variable depending on the cell type. In
HEK cells and COS cells, SGLT1-YFP/CFP was distributed
between intracellular compartments and the plasma mem-
brane, and activity of the transporter depended on the
experimental conditions, with SGLT1 activity and inser-
tion in the plasma membrane being higher in COS cells.
In contrast, SGLT1YFP/CFP’s expression in CHO cells
was very low, due to a higher rate of degradation com-
pared to the rate of synthesis. In these cells, inhibition of
protein degradation by proteasome or lysosome inhibitors
led to SGLT1-YFP/CFP detection by imaging, but the
effects of the two types of inhibitors were dramatically
different.
SGLT1 degradation in CHO and HEK cells
Our data obtained with lysosome and proteasome inhibi-
tors show that both regulate SGLT1-YFP/CFP expression
and trafficking, but in very different ways. Lysosome inhibi-
tors cause accumulation of SGLT1-YFP/CFP in intracellu-
lar bodies, demonstrating SGLT1-YFP/CFP degradation by
lysosomes. In contrast, proteasome inhibitors cause accu-
mulation of SGLT1-YFP/CFP into the plasma membrane,
very likely as a result of lysosomal pathway’s inhibition.
Furthermore, data obtained after stabilizing SGLT1-YFP/
CFP into the plasma membrane with the cholesterol inhibi-
tor show that addition of lysosome inhibitors still causes
rapid accumulation of SGLT1-YFP/CFP in lysosome, with-
out increasing the level of SGLT1-YFP/CFP in the plasma
membrane. On this basis, we conclude that most of the
newly synthesized SGLT1 is targeted to lysosomes for
degradation, while a smaller and slower trafficking fraction
goes to the plasma membrane. These results are consistent
with data obtained with other rapidly cycling membrane-
bound proteins such as connexin43 (Cx43) (Laing et al.
1997; Qin et al. 2003). In comparison, data obtained with
proteasome inhibitors were somewhat less expected.
Indeed, in all three cell lines, the inhibitors caused accumu-
lation of SGLT1-YFP/CFP into the plasma membrane. In
CHO cells, this effect was accompanied by accumulation of
SGLT1-YFP/CFP in intracellular bodies, but in HEK cells,
SGLT1-YFP/CFP was found in the plasma membrane and
in the Golgi, but not in intracellular bodies. These effects of
the lysosome and proteasome inhibitors on SGLT1-YFP
trafficking are very reminiscent of the effects on Cx43,
wherein lysosome inhibitors caused accumulation of the
protein in intracellular bodies, while proteasome inhibitors,
induce accumulation in the membrane. How proteasome
inhibitors cause Cx43 insertion into the membrane still
remains largely unknown.
Studies of inhibition of EGFR and GHR degradation by
proteasome inhibitors may be a key to understanding our
SGLT1 data. It has been shown that inhibition by protea-
some inhibitors of a late step in the lysosomal pathway –
between the late endosome and lysosomes – increases recy-
cling of EGFR and GHR to the plasma membrane (van Ker-
khof et al. 2001; Longva et al. 2002; Alwan et al. 2003;
Lipkowitz 2003). Similar results obtained with SGLT1-YFP/
CFP suggest that the increased membrane insertion of
SGLT1 induced by proteasome inhibitors may result from
inhibition of the lysosomal degradation pathway at a late
stage, which in turn favors recycling of SGLT1 from the
early endosome to the plasma membrane. Such a mecha-
nism would explain our data obtained with HEK cells where
proteasome inhibitors cause accumulation of SGLT1 in the
plasma membrane, while preventing at the same time its
accumulation in intracellular bodies. Indeed, it is logical to
assume that the inhibitors block a step – that is, the late
endosome to lysosome step – which is common to both the
TGN to the lysosomes pathway, denoted A in Figure 2, and
the plasma membrane to the lysosome pathway denoted B
in Figure 2. Furthermore, our observation that SGLT1 pro-
tein levels increase by 34.5% after incubation with the pro-
teasome inhibitor, is also consistent with inhibition of the
lysosomal degradation pathway. Using an HA-tagged ubiq-
uitin, we were not able to show that SGLT1 itself is ubiquiti-
nated (pers. obser.), suggesting that the proteasome
inhibitor does not have a direct effect on the transporter
endocytosis and degradation. However, this does not invali-
date our hypothesis, since the proteasome may target the
transfer process of the cargo proteins rather than the pro-
teins themselves (van Kerkhof et al. 2001; Longva et al.
2002).
SGLT1 internalization in HEK and COS cells
It has been suggested, based on the observation that
SGLT1 activity is upregulated by caveolin, that caveolin
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increases insertion of the transporter in the plasma mem-
brane (Runembert et al. 2002; Lee et al. 2012; Elvira et al.
2013). Our data support this hypothesis and show that
co-expression of SGLT1YFP/CFP with caveolin 1 (Cav1)
causes a significant increase in the insertion of SGLT1-
YFP/CFP in the plasma membrane. The best known role
of caveolin is that of a scaffolding protein, which orga-
nizes and inactivates signaling molecules that are concen-
trated on the cytoplasmic surface of caveolar membranes.
Such inactivation of membrane-bound proteins cannot
account for the stimulatory effect of caveolin on SGLT1.
Then, the role of caveolin is not restricted to that of a
scaffolding protein as it may also interact and regulate the
activity of signaling molecules, including G proteins,
adenylate cyclase, PKC, or the insulin receptor (Smart
et al. 1999; Ishikawa et al. 2005). We carried out experi-
ments to further investigate the regulation of SGLT1
activity by caveolin. As already stated, co-expression of
SGLT1-YFP/CFP with wild-type Cav1 increases the inser-
tion of SGLT1 in the plasma membrane. However, when
SGLT1-YFP was co-expressed with Cav1-mCherry, we
could not find any overlap in the plasma membrane
(Fig. S3). These data indicate that the effect of Cav1 on
SGLT1 insertion in the plasma membrane is indirect and
may involve PKA, which is regulated by cytoplasmic cave-
olin (Lee et al. 2012), PI3K or PKC as reported elsewhere
(Oka et al. 1997; Zundel et al. 2000). To further rule out
a direct effect of caveolin on SGLT1 insertion in the
plasma membrane, we tested the effect of the dominant
negative dynamin K44A, which stabilizes caveolin in the
plasma membrane (Henley et al. 1998; Oh et al. 1998;
Smart et al. 1999; Parton and del Pozo 2013). Accord-
ingly, our data obtained with HEK and COS cells show
that expression of dynamin K44A causes caveolin accu-
mulation in membrane domains. However, this effect of
dynamin K44A on caveolin occurs without a parallel
increase in membrane-bound SGLT1-YFP, further sup-
porting the hypothesis that regulation of SGLT1 traffick-
ing by caveolin is indirect and does not require caveolin’s
stabilization in the membrane.
Thus, SGLT1 internalization may be lipid raft-depen-
dent, but caveolin-independent. A number of pathways
have been identified that are cholesterol-mediated, but
caveolin-independent. For instance, macropinocytosis is
clathrin and dynamin-independent, but is regulated by
MbCD. In addition to be regulated by MbCD, this path-
way is controlled by PIP2 and the GTPase Cdc42, which
controls actin polymerization (Lariccia et al. 2011). We
found that SGLT1 internalization is modulated by the
inhibitor of PI3K wortmannin, but is insensitive to over-
expression of the dominant negative Cdc42N17 (data not
shown). These results indicate that SGLT1 endocytosis is
not mediated via macropinocytosis. There are other
pathways that are lipid raft-dependent and caveolin-inde-
pendent, such as the flotillin-dependent pathway, or the
Arf6-dependent pathway (El-Sayed and Harashima 2013),
which may regulate SGLT1 internalization. Future experi-
ments will have to be carried out with RNAi against flo-
tillin and Arf6 to test for the possible role of these other
cholesterol-dependent pathways in SGLT1 translocation.
Physiological relevance: A model for
polarized epithelial cells
In MDCK cells, SGLT transits from the whole cell mem-
brane to the apical membrane as tight junctions form and
the cells become polarized. Exposure of these polarized
cells to the cholesterol inhibitor MbCD causes SGLT1
depletion from the apical membrane and accumulation
into the rest of the membrane (Suzuki et al. 2006). How
cholesterol regulates SGLT1 membrane targeting in these
polarized cells remains unclear. Our data obtained with
HEK and COS cells exposed to MbCD show that choles-
terol depletion causes accumulation of SGLT1 in the
plasma membrane, suggesting that in the absence of
cholesterol, SGLT1 endocytosis is inhibited. This accumu-
lation of SGLT1 in the plasma membrane in response to
MbCD is consistent with reports obtained with other pro-
teins, including cholera toxin and GLUT transporters
(Ivanov 2008). In epithelial cells, protein targeting to the
apical membrane may occur via a direct route from the
Golgi to the apical membrane, or a transcytotic route
with a stopover at the basolateral membrane (Rodriguez-
Boulan et al. 2005; Lakkaraju and Rodriguez-Boulan
2007). Based on this model, our MbCD data are best
explained, assuming that in polarized epithelial cells,
SGLT1 targeting to the apical membrane proceeds with a
stopover at the basolateral membrane where regulation of
trafficking by cholesterol synthesis takes place (see Fig. 9).
Under normal conditions, SGLT1 would be transiently
inserted into the basolateral membrane, on its way to the
apical membrane, but following membrane depletion of
cholesterol, endocytosis of SGLT1 at the basolateral mem-
brane would be inhibited and SGLT1 would accumulate
in the basolateral membrane. As a consequence of inhibi-
tion of this forward traffic, there would be depletion of
SGLT1 from the apical membrane. When comparing the
effects of different modulators of endocytosis and degra-
dation, we found that regulation of SGLT1 and GLUT4
trafficking was different. Indeed, we found, consistent
with clathrin-dependent internalization of GLUT4 (Al-
Hasani et al. 1998; Kao et al. 1998; Hou and Pessin 2007;
Hou et al. 2009), that internalization of GLUT4 was
MbCD-insensitive and dynamin-dependent. Based on
these observations, we propose the model depicted in Fig-
ure 9 where the transcytotic pathway between the
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basolateral membrane and the apical membrane is lipid
raft-mediated; with this assumption alone we can explain
SGLT1 preferential targeting to the apical membrane and
GLUTs targeting to the basolateral membrane.
Stress-related expression of SGLT1 in muscle
In cardiac muscle, SGLT1 is chronically upregulated dur-
ing ischemia and in diabetes (Banerjee et al. 2009) and its
overexpression causes hypertrophy (Ramratnam et al.
2014). In addition to these chronic effects, increased
activity of SGLT1 occurs acutely, within 1 h, in response
to leptin and insulin (Banerjee et al. 2009). Similarly, in
skeletal muscle, the activity of SGLT1 increases within 1 h
in response to exercise (E.M. Wright personal communi-
cation). The chronic effects of diabetes and ischemia are
best explained by increased gene expression, but there is
no clear understanding of the mechanism of acute upreg-
ulation of SGLT1. This rapid increase in activity may
result from insertion of premade transporter into the
plasma membrane, or as supported by our CHO traffick-
ing data, from increased expression of SGLT1 after inhibi-
tion of protein degradation due to physiological or
pathological stress. This hypothesis, which is consistent
with the well-known upregulation of ubiquitin ligases by
ER stress (Shen et al. 2007) is presently being tested in
our laboratory, using isolated muscle fibers and the
FRET-based glucose sensor.
In summary, in mammalian cells, newly synthesized
SGLT1 may be targeted to lysosomes for degradation, or
directed to the plasma membrane for glucose transport.
Once in the plasma membrane, SGLT1 can be internal-
ized via a lipid raft-dependent process to be either recy-
cled to the plasma membrane, or directed to lysosomes
for degradation under control of the proteasome. In con-
trast, GLUT4 internalization is lipid raft-independent, but
degradation involves lysosomes. Having established how
SGLT and GLUT are internalized and degraded in nonpo-
larized cells, it would be relevant to determine how the
processes, which we characterized, influence the targeting
of these transporters to the apical and basolateral mem-
brane in polarized cells.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Fig S1. SGLT1 and SGLT2-dependent glucose transport
measured in COS cells, expressing the FRET-based glu-
cose sensor Flip600lM together with either wt SGLT1 or
wt SGLT2.
Fig S2. Confocal images of the Plasma Membrane
marker-mCherry (PMmCherry) (left panel) and SGLT1-
YFP after incubation with the proteasome inhibitor MG-
262 (1 mM) (middle panel). The right panel is an overlap
of images A and B.
Fig S3. Confocal images of punctate Cav1-mCherry at the
cell periphery (left panel) and of membrane-inserted
SGLT1-YFP, after incubation with the proteasome inhibi-
tor MG-262 (1 mM) (middle panel). The right panel
shows no overlap between Cav1-mCherry and SGLT1-
YFP.
Fig S4. Confocal images of Lamp1-mcherry, labeling a
dense pattern of lysosomes throughout the cytoplasm (left
panel), and of SGLT1-YFP, labeling a less dense punctate
pattern (middle panel). The overlap of images A and B
(right panel) shows that SGLT1 is targeted to some lyso-
somes (arrows).
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